Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chro...
June 08 2021 - 8:30AM
Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage
biopharmaceutical company dedicated to discovering, developing and
commercializing first-in-class oral enzyme therapeutics to treat
patients with rare and severe metabolic and kidney disorders, today
announced that it will host a key opinion leader (KOL) webinar
focused on ALLN-346, a novel oral biologic currently in Phase 1
development for the treatment of gout in the setting of chronic
kidney disease (CKD), on Wednesday, June 16, 2021 at 12:00 pm
Eastern Daylight Time.
The webinar will feature a presentation by KOL Robert
Terkeltaub, M.D., University of California San Diego School of
Medicine, who will discuss the current treatment landscape and
unmet medical need in treating patients with gout in the setting of
CKD. Dr. Terkeltaub will be available to answer questions following
the formal presentations.
Allena's management team will also provide an overview of the
ongoing clinical development program and potential commercial
opportunity for ALLN-346, which is designed to be a first-in-class,
orally administered, non-absorbed, urate-degrading enzyme. Allena
recently initiated a Phase 1 multiple-ascending dose study in
healthy volunteers and remains on track to initiate a Phase 2a
program in patients with hyperuricemia during the third
quarter.
Robert Terkeltaub, M.D., is Professor of Medicine at the
University of California San Diego School of Medicine and also is
Section Chief of Rheumatology at the Veterans Administration
Medical Center in San Diego. Dr. Terkeltaub received his medical
degree at McGill University in Montreal, Canada, and completed
McGill-based residency and training programs at Montreal General
Hospital in Rheumatology and Internal Medicine. Dr. Terkeltaub has
been the recipient of numerous teaching awards at the University of
California at San Diego. Dr. Terkeltaub is an Associate Editor of
Arthritis and Rheumatism and serves on numerous Study Sections in
arthritis and vascular biology.
To register for the webinar, please click here.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical
company dedicated to discovering, developing and commercializing
first-in-class, oral biologic therapeutics to treat patients with
rare and severe metabolic and kidney disorders. Allena’s lead
product candidate, reloxaliase, is currently being evaluated in a
pivotal Phase 3 clinical program for the treatment of enteric
hyperoxaluria, a metabolic disorder characterized by markedly
elevated urinary oxalate levels and commonly associated with kidney
stones, chronic kidney disease and other serious kidney disorders.
Allena is also developing ALLN-346 for the treatment of
hyperuricemia and gout in the setting of advanced chronic kidney
disease, with a Phase 1 multiple-ascending dose study currently in
progress and a Phase 2a program planned for the second half of
2021.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, without limitation, statements concerning the future
clinical, regulatory and commercial potential of reloxaliase,
statements regarding enrollment and the timing of the planned
interim analysis in the URIROX-2 trial, the timing of topline data
from this trial, statements regarding Allena’s strategy of pursuing
a BLA submission for reloxaliase based upon data from its URIROX
program using the accelerated approval regulatory pathway, which
strategy is predicated on the FDA’s agreement with our predictive
model supporting a relationship between UOx levels and stone
formation rates, statements regarding Allena’s development of
ALLN-346 including the timing of planned clinical trials and the
announcement of topline date for these trials, and statements
regarding Allena’s financial position and need for capital. Any
forward-looking statements in this press release are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: market and other
conditions, the timing for completion of Allena’s clinical trials
of its product candidates, risks associated with obtaining,
maintaining and protecting intellectual property; risks associated
with Allena’s ability to enforce its patents against infringers and
defend its patent portfolio against challenges from third parties;
the risk of competition from other companies developing products
for similar uses; risks associated with Allena’s financial
condition and its need to obtain additional funding to support its
business activities, including the future clinical development of
reloxaliase and its ability to continue as a going concern; risks
associated with Allena’s dependence on third parties; and risks
related to the COVID-19 coronavirus. For a discussion of other
risks and uncertainties, and other important factors, any of which
could cause Allena’s actual results to differ from those contained
in the forward-looking statements, see the section entitled “Risk
Factors” in Allena’s Annual Report on Form 10-Q for the quarter
ended March 31, 2021, as well as discussions of potential risks,
uncertainties and other important factors in Allena’s subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Allena undertakes no duty to update this information unless
required by law.
Investor ContactAshley RobinsonLifeSci
Advisors, LLC617-430-7577
Allena Pharmaceuticals (NASDAQ:ALNA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Allena Pharmaceuticals (NASDAQ:ALNA)
Historical Stock Chart
From Oct 2023 to Oct 2024